PTGX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 5, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 25, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Protagonist Reports Third Quarter 2026 Financial Results, Highlighting MIMRYLO FDA Approval, $275 Million in Partner Payments, and $300 Million Share Repurchase

Nov 5, 2026

8-K

Protagonist Therapeutics Reports Q2 2026 Financial Results and Pipeline Progress

Aug 5, 2026

8-K

Protagonist Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 18, 2026

8-K

Protagonist Therapeutics Reports Q1 2026 Financial Results and Corporate Updates

May 5, 2026

8-K

Protagonist Reports Q4 and Full Year 2025 Results; Expects to Opt-Out of Rusfertide Profit Sharing in Q2 2026

Feb 25, 2026

8-K

Protagonist Therapeutics Provides Overview of Development Pipeline and Collaborations

Jan 12, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

Shares amount: 2,750,000

Aug 11, 2023

424B5

SHELF OFFERING | Shares amount: 5,000,000 | Share price: $20.00 | Offering amount: $100,000,000.00 | Bank: J.P. Morgan, Jefferies, Piper Sandler, BTIG, H.C. Wainwright & Co.

Apr 5, 2023

424B5

.00 | Offering amount: $100,000,000.00 | Bank: J.P. Morgan, Jefferies, Piper Sandler, BTIG, H.C. Wainwright & Co.

Apr 4, 2023

424B5

3,046,358 Shares-

Jun 17, 2021

424B5

Common Stock Preferred Stock Debt Securities Warrants-

Jun 14, 2021

424B5

4,761,904 Shares-

Dec 11, 2020

Registrations

TYPE

HEADLINE

FILED AT

S-8 POS